Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition

Circulation

Volumn 102, Issue 1, 2000, Pages 35-41

  Prasad, Abhiram ^a   Narayanan, Suresh ^a   Husain, Syed ^a   Padder, Feroz ^a   Waclawiw, Myron ^a   Epstein, Neil ^a   Quyyumi, Arshed A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Acetylcholine; Angiotensin; Atherosclerosis; Coronary disease; Genes

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; GENE DELETION; GENE INSERTION; GENETIC RISK; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0034604252     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.1.35     Document Type: Article

References (32)

1. Ross R. The pathogenesis of atherosclerosis: a prospective for the 1990s. Nature. 1993;362:801-809.
2. Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation. J Clin Invest. 1995;95:1747-1755.
3. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996;94: 258-265.
4. O'Driscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest. 1997;100:678-684.
5. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
6. Villard E, Soubrier F. Molecular biology and genetics of the angiotensin-I-converting enzyme: potential implications in cardiovascular diseases. Cardiovasc Res. 1996;32:999-1007.
7. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197-205.
8. Villard E, Tiret L, Visvikis S, et al. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by 2-QTL segregation-linkage analysis. Am J Hum Genet. 1996;58:1268-1278.
9. Samani NJ, Thompson JR, O'Toole L, et al. A meta-analysis of the association of the deletion allele of the angiotensin converting enzyme gene with myocardial infarction. Circulation. 1996;94:708-712.
10. Nakai K, Itoh C, Miura Y, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation. 1994; 90:2199-2202.
11. Mattu RK, Needham EW, Galton DJ, et al. A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation. 1995;91: 270-274.
12. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 1995;332:706-711.
13. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. ACE gene polymorphism: ischemic heart disease and longevity in 10 150 individuals: a case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation. 1997;95:2358-2367.
14. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86: 1343-1346.
15. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation. 1995;92:1387-1388.
16. Prasad A, Husain S, Quyyumi AA. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin converting enzyme inhibition: a potential role of bradykinin. J Am Coll Cardiol. 1999;33:796-804.
17. el-Tamimi H, Mansour M, Wargovich TJ, et al. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease: endothelial function revisited. Circulation. 1994;89:45-51.
18. Prasad A, Husain S, Quyyumi AA. Human peripheral endothelial dysfunction and nitric oxide bioavailability improves with angiotensin converting enzyme inhibition. Am J Cardiol. 1999;84:1-6.
19. Nakamura M, Funakoshi T, Arakawa N, et al. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with heart failure. J Am Coll Cardiol. 1994;24: 1321-1327.
20. Sudhir K, Chou TM, Hutchison SJ, et al. Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo. Circulation. 1996; 93:1734-1739.
21. Nakashima M, Mombouli J-V, Taylor AA, et al. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest. 1993;92:2867-2871.
22. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest. 1996;97: 1916-1923.
23. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin type 1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000;101:2349-2354.
24. Groves P, Kurz S, Just H, et al. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424-3430.
25. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 1997;81:848-856.
26. Prasad A, Narayanan S, Epstein N, et al. The genetic control of coronary vasomotor tone: role of angiotensin converting enzyme gene polymorphism. J Am Coll Cardiol. 1999;33:312A. Abstract.
27. Celermajer DS, Sorensen KE, Barley J, et al. Angiotensin-converting enzyme genotype is not associated with endothelial dysfunction in subjects without other coronary risk factors. Atherosclerosis. 1994;111: 121-126.
28. Alhenc-Gelas F, Richard J, Courbon D, et al. Distribution of plasma angiotensin I-converting enzyme levels in healthy men: relationship to environmental and hormonal parameters. J Lab Clin Med. 1991;117: 33-39.
29. Buikema H, Pinto YM, Rooks G, et al. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J. 1996;17:787-794.
30. Ueda S, Elliott HL, Morton JJ, et al. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension. 1995;25:1266-1269.
31. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94: 2756-2767.
32. Powell JS, Clozel JP, Muller RKM, et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186-188.